Ketamine
The Daily Hit: January 10, 2024
The Daily Hit is a recap of the top financial news stories for Jan. 10, 2024. On the Site MSOs Not Rushing to Open New York Retail Shops Although six…
The Daily Hit is a recap of the top financial news stories for Jan. 10, 2024.
On the Site
MSOs Not Rushing to Open New York Retail Shops
Although six marijuana multistate operators got the thumbs up from New York regulators last month to open retail shops, thus far only one has done so, potentially indicating that the companies are deprioritizing retail in the state in favor of the wholesale market. Read more here.
Connecticut Marijuana Sales Pass $274 Million in First Year of Recreational
One of New England’s newest adult-use cannabis markets, Connecticut, surpassed $274 million in total marijuana sales last year with its 31 dispensaries, and ended 2023 with the highest month of sales in December, the state announced Wednesday. Read more here.
PharmaTher Expecting FDA Approval for Ketamine Treatment in April
Toronto-based PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is expecting to get full approval from the U.S. Food and Drug Administration (FDA) in April for a ketamine-based treatment it’s developed to be used for a wide array of “pain, mental health, and neurological disorders,” the company announced Wednesday. Read more here.
Zuanic Initiates Coverage on StateHouse, Gold Flora
Cannabis equity analyst Pablo Zuanic of Zuanic & Associates has initiated coverage on Statehouse Holdings Inc. (OTC: STHZF) with a neutral rating and Gold Flora (OTC: GRAM) with an overweight rating. Read more here.
Willow Biosciences Signals Commercial Leap for Synthetics
Biotech firm Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) announced a record rise in its 2023 revenue and outlined an ambitious plan for further growth in 2024. Read more here.
In Other News
Rescheduling
Tilray Brands believes it can get into the medical marijuana business in the U.S. pretty quickly if the Biden administration reclassifies cannabis as a Schedule 3 drug sometime this year, CEO Irwin Simon tells WSJ. Read more here.
Akerna
Akerna Corp. (Nasdaq: KERN) (“Akerna”) announced a special stockholder meeting scheduled for Jan. 29, to vote on the proposed merger with Gryphon Digital Mining, Inc. Read more here.
The post The Daily Hit: January 10, 2024 appeared first on Green Market Report.
ketamine
-
Psychedelics1 week agoCybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin5 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics4 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days agoOptimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research